Comment from Obesity Medicine Association

Summary: The Obesity Medicine Association (OMA) opposes the inclusion of MOTS-c on the section 503A Bulk Drug Substances List. They argue that compounded peptides lack the rigorous FDA review required for safety and efficacy and advocate for clinical trial testing before such substances are marketed or used.